Ascendis Pharma A/S (ASND)
| Market Cap | 16.77B |
| Revenue (ttm) | 998.25M +134.8% |
| Net Income | 571.81M |
| EPS | 9.26 |
| Shares Out | 65.92M |
| PE Ratio | 26.97 |
| Forward PE | 37.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,995 |
| Open | 251.76 |
| Previous Close | 249.85 |
| Day's Range | 251.76 - 257.57 |
| 52-Week Range | 203.80 - 282.15 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 308.43 (+21.24%) |
| Earnings Date | Aug 13, 2026 |
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $308.43, which is an increase of 21.24% from the latest price.
News
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thur...
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.
Ascendis Pharma Slides: Study update presentation
Ascendis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Ascendis Pharma price target raised to $275 from $256 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Ascendis Pharma (ASND) to $275 from $256 and keeps an Overweight rating on the shares. Q2 earnings should reinforce a shift from…
Ascendis Pharma price target raised to $280 from $275 at RBC Capital
RBC Capital raised the firm’s price target on Ascendis Pharma (ASND) to $280 from $275 and keeps an Outperform rating on the shares as part of a broader research note…
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial
Ascendis Pharma (ASND) announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP in children with achondroplasia. In the trial, TransCon CNP-t...
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly T...
Ascendis Pharma added to multiple Russell U.S. Indexes
Ascendis Pharma (ASND) announced that the company has been added to the broad-market Russell 3000 Index, the large-cap Russell 1000 Index, the small-to-mid-cap Russell 2500 Index, and the Russell Midc...
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell...
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with...
Ascendis Pharma completes Phase 3 PaTHway Trial
Ascendis Pharma (ASND) announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH demonstrated sustained efficacy and safety in adults with hyp...
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with T...
Ascendis Pharma announces five-year data from PaTH Forward Trial
Ascendis Pharma (ASND) announced five-year data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH demonstrated sustained efficacy and safety in adults with hypopar...
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COP...
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
Oppenheimer believes Ascendis Pharma (ASND) is oversold following a development in the ongoing ITC investigation into Yuviwel initiated by BioMarin (BMRN). Should the recommendation in a recent ITC st...
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achon...
Ascendis Pharma initiated with a Buy at Citi
Citi analyst Eric Joseph initiated coverage of Ascendis Pharma (ASND) with a Buy rating and $355 price target Citi is “impressed” with Yorvipath’s launch and sees potential upside to consensus…
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI
Evercore ISI raised the firm’s price target on Ascendis Pharma (ASND) to $329 from $324 and keeps an Outperform rating on the shares.
Ascendis Pharma price target raised to $345 from $342 at Barclays
Barclays raised the firm’s price target on Ascendis Pharma (ASND) to $345 from $342 and keeps an Overweight rating on the shares post the Q1 report. The company sounds confident…
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
Wells Fargo lowered the firm’s price target on Ascendis Pharma (ASND) to $326 from $330 and keeps an Overweight rating on the shares. The firm notes Yorvipath is on a…
Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)
Reports Q1 revenue EUR 246.6M, consensus EUR 269.64M. Reports Q1 Yorvipath revenue EUR 197M. Reports Q1 Skytrofa revenue EUR 44M. “The FDA approval of YUVIWEL, our third consecutive TransCon product,…
Ascendis Pharma Earnings Call Transcript: Q1 2026
Q1 2026 saw rapid revenue growth and profitability, driven by the FDA approval of YUVIWEL and strong uptake of YORVIPATH and SKYTROFA. Total revenue reached EUR 247 million, with robust patient and prescriber growth, and a strengthened balance sheet through asset sales and debt redemption.
Ascendis Pharma Earnings release: Q1 2026
Ascendis Pharma released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Ascendis Pharma Reports First Quarter 2026 Financial Results
- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollm...